Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

but the safety and efficacy of odronextamab has not been fully evaluated by any other regulatory authority. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and ...

Regeneron recently announced that the primary ... REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or ...

but the safety and efficacy of odronextamab has not been fully evaluated by any other regulatory authority. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and ...